Jun-Ling Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jun-Ling Yang has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Chuan Li
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai China
9 shared publications Feng-Qing Wang
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
5 shared publicationsFei-Fei Du
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
4 shared publicationsChen Cheng
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
2 shared publicationsFang Xu
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
2 shared publications- Fei-Fei Du
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
2 shared publications
Latest Publications
- Open Access
- 1 June 2025
- Published by Wolters Kluwer Health in Acupuncture and Herbal Medicine
- Vol. 5 (2) , 173-192
Human pharmacokinetics and drug interaction potential of GuHong: an intravenous herbal formulation for managing ischemic stroke
Objective: Unlike for drug-drug interactions, rigorous guidelines for assessing herb-drug interactions are nonexistent. GuHong is an intravenous herbal formulation used as adjunct therapy for the management of ischemic stroke. This investigation aimed to evaluate its potential to precipitate pharmacokinetic drug interactions. To facilitate the potential assessment, a human multi-compound pharmacokinetic study, along with associated supportive studies, was conducted to pinpoint GuHong compounds for testing. Methods: After analyzing the chemical composition of GuHong, a pharmacokinetic study was conducted in healthy subjects who received GuHong intravenously to identify its significantly exposed compounds and their pharmacokinetics. In addition, supportive rat and in vitro studies were conducted to assess the hepatic and renal disposition of these compounds, including their metabolism and transport. The potential of GuHong to precipitate drug interactions was evaluated in vitro using significantly exposed compounds, which were tested for their effects on drug-metabolizing enzymes and drug transporters listed in the ICH M12 Guideline (2024), with a focus on inhibition and induction. Samples were analyzed by liquid chromatography-mass spectrometry. Results: A total of 54 constituents (0.01–27.18 μmol/day) derived from Carthamus tinctorius flowers (Honghua) and N-acetyl-L-glutamine (3,090 μmol/day) were detected in GuHong. Following intravenous administration of GuHong, hydroxysafflor yellow A emerged as the principal circulating compound from Honghua. Saffloquinoside D, kaempferol-3-O-rutinoside, kaempferol-3-O-sophoroside, 8-hydroxycinnamic acid-8-O-glucoside, coumaric acid-4-O-glucoside, and chlorogenic acid, also from Honghua, were detected but at low plasma levels. Hydroxysafflor yellow A, primarily eliminated via glomerular filtration-based renal excretion, exhibited the characteristics of an intravenous “hard drug.” N-Acetyl-L-glutamine was another major circulating compound of GuHong and was eliminated through renal excretion and hydrolysis to L-glutamine. GuHong had a low potential to precipitate pharmacokinetic drug interactions. Conclusions: The low drug interaction potential of GuHong is advantageous for its use in the treatment of ischemic stroke in the context of polypharmacy. The methodology developed here can be applied to the study of other complex herbal medicines for their pharmacokinetic drug interaction potential.
- 1 June 2025
- Published by Wolters Kluwer Health in Acupuncture and Herbal Medicine
- Vol. 5 (2) , 173-192
Open AccessHuman pharmacokinetics and drug interaction potential of GuHong: an intravenous herbal formulation for managing ischemic stroke
Objective: Unlike for drug-drug interactions, rigorous guidelines for assessing herb-drug interactions are nonexistent. GuHong is an intravenous herbal formulation used as adjunct therapy for the management of ischemic stroke. This investigation aimed to evaluate its potential to precipitate pharmacokinetic drug interactions. To facilitate the potential assessment, a human multi-compound pharmacokinetic study, along with associated supportive studies, was conducted to pinpoint GuHong compounds for testing. Methods: After analyzing the chemical composition of GuHong, a pharmacokinetic study was conducted in healthy subjects who received GuHong intravenously to identify its significantly exposed compounds and their pharmacokinetics. In addition, supportive rat and in vitro studies were conducted to assess the hepatic and renal disposition of these compounds, including their metabolism and transport. The potential of GuHong to precipitate drug interactions was evaluated in vitro using significantly exposed compounds, which were tested for their effects on drug-metabolizing enzymes and drug transporters listed in the ICH M12 Guideline (2024), with a focus on inhibition and induction. Samples were analyzed by liquid chromatography-mass spectrometry. Results: A total of 54 constituents (0.01–27.18 μmol/day) derived from Carthamus tinctorius flowers (Honghua) and N-acetyl-L-glutamine (3,090 μmol/day) were detected in GuHong. Following intravenous administration of GuHong, hydroxysafflor yellow A emerged as the principal circulating compound from Honghua. Saffloquinoside D, kaempferol-3-O-rutinoside, kaempferol-3-O-sophoroside, 8-hydroxycinnamic acid-8-O-glucoside, coumaric acid-4-O-glucoside, and chlorogenic acid, also from Honghua, were detected but at low plasma levels. Hydroxysafflor yellow A, primarily eliminated via glomerular filtration-based renal excretion, exhibited the characteristics of an intravenous “hard drug.” N-Acetyl-L-glutamine was another major circulating compound of GuHong and was eliminated through renal excretion and hydrolysis to L-glutamine. GuHong had a low potential to precipitate pharmacokinetic drug interactions. Conclusions: The low drug interaction potential of GuHong is advantageous for its use in the treatment of ischemic stroke in the context of polypharmacy. The methodology developed here can be applied to the study of other complex herbal medicines for their pharmacokinetic drug interaction potential.
- 1 May 2025
- Published by Elsevier in Phytomedicine
- Vol. 143, 156716
Guiding precision medicine strategy for intravenous ginsenosides via pharmacokinetic-informed bioinformatic approaches: a study on XueShuanTong
- 1 May 2025
- Published by Elsevier in Phytomedicine
- Vol. 143, 156716
Guiding precision medicine strategy for intravenous ginsenosides via pharmacokinetic-informed bioinformatic approaches: a study on XueShuanTong
- 22 April 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 349, 119864
Risk assessment of CYP3A induction by ginsenoside’s metabolites from oral Panax notoginseng (sanqi) extract
- 22 April 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 349, 119864
Risk assessment of CYP3A induction by ginsenoside’s metabolites from oral Panax notoginseng (sanqi) extract
- 29 February 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 326, 117967
Positive benefit-risk ratio of Psoraleae Fructus: Comprehensive safety assessment and osteogenic effects in rats
- 29 February 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 326, 117967
Positive benefit-risk ratio of Psoraleae Fructus: Comprehensive safety assessment and osteogenic effects in rats
- 9 February 2024
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 22 (2) , 178-192
Composition analysis of Compound Shenhua Tablet, a seven-herb Chinese medicine for IgA nephropathy: evaluation of analyte-capacity of the assays
- 9 February 2024
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 22 (2) , 178-192
Composition analysis of Compound Shenhua Tablet, a seven-herb Chinese medicine for IgA nephropathy: evaluation of analyte-capacity of the assays
- Open Access
- 29 July 2019
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 40 (10) , 1351-1363
Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions
XueShuanTong, a lyophilized extract of Panax notoginseng roots (Sanqi) for intravenous administration, is extensively used as add-on therapy in the treatment of ischemic heart and cerebrovascular diseases and comprises therapeutically active ginsenosides. Potential for XueShuanTong–drug interactions was determined; the investigation focused on cytochrome P450 (CYP)3A induction and organic anion-transporting polypeptide (OATP)1B inhibition. Ginsenosides considerably bioavailable for drug interactions were identified by dosing XueShuanTong in human subjects and their interaction-related pharmacokinetics were determined. The CYP3A induction potential was determined by repeatedly dosing XueShuanTong for 15 days in human subjects and by treating cryopreserved human hepatocytes with circulating ginsenosides; midazolam served as a probe substrate. Joint inhibition of OATP1B by XueShuanTong ginsenosides was assessed in vitro, and the data were processed using the Chou–Talalay method. Samples were analyzed by liquid chromatography/mass spectrometry. Ginsenosides Rb1, Rd, and Rg1 and notoginsenoside R1 were the major circulating XueShuanTong compounds; their interaction-related pharmacokinetics comprised compound dose-dependent levels of systemic exposure and, for ginsenosides Rb1 and Rd, long terminal half-lives (32‒57 and 58‒307 h, respectively) and low unbound fractions in plasma (0.8%‒2.9% and 0.4%‒3.0%, respectively). Dosing XueShuanTong did not induce CYP3A. Based on the pharmacokinetics and inhibitory potency of the ginsenosides, XueShuanTong was predicted to have high potential for OATP1B3-mediated drug interactions (attributed chiefly to ginsenoside Rb1) suggesting the need for further model-based determination of the interaction potential for XueShuanTong and, if necessary, a clinical drug interaction study. Increased awareness of ginsenosides’ pharmacokinetics and XueShuanTong–drug interaction potential will help ensure the safe use of XueShuanTong and coadministered synthetic drugs.
- 29 July 2019
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 40 (10) , 1351-1363
Open AccessIntravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions
XueShuanTong, a lyophilized extract of Panax notoginseng roots (Sanqi) for intravenous administration, is extensively used as add-on therapy in the treatment of ischemic heart and cerebrovascular diseases and comprises therapeutically active ginsenosides. Potential for XueShuanTong–drug interactions was determined; the investigation focused on cytochrome P450 (CYP)3A induction and organic anion-transporting polypeptide (OATP)1B inhibition. Ginsenosides considerably bioavailable for drug interactions were identified by dosing XueShuanTong in human subjects and their interaction-related pharmacokinetics were determined. The CYP3A induction potential was determined by repeatedly dosing XueShuanTong for 15 days in human subjects and by treating cryopreserved human hepatocytes with circulating ginsenosides; midazolam served as a probe substrate. Joint inhibition of OATP1B by XueShuanTong ginsenosides was assessed in vitro, and the data were processed using the Chou–Talalay method. Samples were analyzed by liquid chromatography/mass spectrometry. Ginsenosides Rb1, Rd, and Rg1 and notoginsenoside R1 were the major circulating XueShuanTong compounds; their interaction-related pharmacokinetics comprised compound dose-dependent levels of systemic exposure and, for ginsenosides Rb1 and Rd, long terminal half-lives (32‒57 and 58‒307 h, respectively) and low unbound fractions in plasma (0.8%‒2.9% and 0.4%‒3.0%, respectively). Dosing XueShuanTong did not induce CYP3A. Based on the pharmacokinetics and inhibitory potency of the ginsenosides, XueShuanTong was predicted to have high potential for OATP1B3-mediated drug interactions (attributed chiefly to ginsenoside Rb1) suggesting the need for further model-based determination of the interaction potential for XueShuanTong and, if necessary, a clinical drug interaction study. Increased awareness of ginsenosides’ pharmacokinetics and XueShuanTong–drug interaction potential will help ensure the safe use of XueShuanTong and coadministered synthetic drugs.
- Open Access
- 16 October 2018
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 40 (6) , 833-849
Multiple circulating saponins from intravenous ShenMai inhibit OATP1Bs in vitro: potential joint precipitants of drug interactions
ShenMai, an intravenous injection prepared from steamed Panax ginseng roots (Hongshen) and Ophiopogon japonicus roots (Maidong), is used as an add-on therapy for coronary artery disease and cancer; saponins are its bioactive constituents. Since many saponins inhibit human organic anion-transporting polypeptides (OATP)1B, this investigation determined the inhibition potencies of circulating ShenMai saponins on the transporters and the joint potential of these compounds for ShenMai-drug interaction. Circulating saponins and their pharmacokinetics were characterized in rats receiving a 30-min infusion of ShenMai at 10 mL/kg. Inhibition of human OATP1B1/1B3 and rat Oatp1b2 by the individual saponins was investigated in vitro; the compounds’ joint inhibition was also assessed in vitro and the data was processed using the Chou–Talalay method. Plasma protein binding was assessed by equilibrium dialysis. Altogether, 49 saponins in ShenMai were characterized and graded into: 10–100 μmol/day (compound doses from ShenMai; 7 compounds), 1–10 μmol/day (17 compounds), and 1, Rb2, Rc, Rd, Ra1, Rg3, Ra2, and Ra3, protopanaxatriol-type ginsenosides Rg1, Re, Rg2, and Rf, and ginsenoside Ro. The protopanaxadiol-type ginsenosides exhibited maximum plasma concentrations of 2.1–46.6 μmol/L, plasma unbound fractions of 0.4–1.0% and terminal half-lives of 15.6–28.5 h (ginsenoside Rg3, 1.9 h), while the other ginsenosides exhibited 0.1–7.7 μmol/L, 20.8–99.2%, and 0.2–0.5 h, respectively. The protopanaxadiol-type ginsenosides, ginsenosides without any sugar attachment at C-20 (except ginsenoside Rf), and ginsenoside Ro inhibited OATP1B3 more potently (IC50, 0.2–3.5 µmol/L) than the other ginsenosides (≥22.6 µmol/L). Inhibition of OATP1B1 by ginsenosides was less potent than OATP1B3 inhibition. Ginsenosides Rb1, Rb2, Rc, Rd, Ro, Ra1, Re, and Rg2 likely contribute the major part of OATP1B3-mediated ShenMai-drug interaction potential, in an additive and time-related manner.
- 16 October 2018
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 40 (6) , 833-849
Open AccessMultiple circulating saponins from intravenous ShenMai inhibit OATP1Bs in vitro: potential joint precipitants of drug interactions
ShenMai, an intravenous injection prepared from steamed Panax ginseng roots (Hongshen) and Ophiopogon japonicus roots (Maidong), is used as an add-on therapy for coronary artery disease and cancer; saponins are its bioactive constituents. Since many saponins inhibit human organic anion-transporting polypeptides (OATP)1B, this investigation determined the inhibition potencies of circulating ShenMai saponins on the transporters and the joint potential of these compounds for ShenMai-drug interaction. Circulating saponins and their pharmacokinetics were characterized in rats receiving a 30-min infusion of ShenMai at 10 mL/kg. Inhibition of human OATP1B1/1B3 and rat Oatp1b2 by the individual saponins was investigated in vitro; the compounds’ joint inhibition was also assessed in vitro and the data was processed using the Chou–Talalay method. Plasma protein binding was assessed by equilibrium dialysis. Altogether, 49 saponins in ShenMai were characterized and graded into: 10–100 μmol/day (compound doses from ShenMai; 7 compounds), 1–10 μmol/day (17 compounds), and 1, Rb2, Rc, Rd, Ra1, Rg3, Ra2, and Ra3, protopanaxatriol-type ginsenosides Rg1, Re, Rg2, and Rf, and ginsenoside Ro. The protopanaxadiol-type ginsenosides exhibited maximum plasma concentrations of 2.1–46.6 μmol/L, plasma unbound fractions of 0.4–1.0% and terminal half-lives of 15.6–28.5 h (ginsenoside Rg3, 1.9 h), while the other ginsenosides exhibited 0.1–7.7 μmol/L, 20.8–99.2%, and 0.2–0.5 h, respectively. The protopanaxadiol-type ginsenosides, ginsenosides without any sugar attachment at C-20 (except ginsenoside Rf), and ginsenoside Ro inhibited OATP1B3 more potently (IC50, 0.2–3.5 µmol/L) than the other ginsenosides (≥22.6 µmol/L). Inhibition of OATP1B1 by ginsenosides was less potent than OATP1B3 inhibition. Ginsenosides Rb1, Rb2, Rc, Rd, Ro, Ra1, Re, and Rg2 likely contribute the major part of OATP1B3-mediated ShenMai-drug interaction potential, in an additive and time-related manner.
- Open Access
- 20 April 2015
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 36 (5) , 627-643
Methylation and its role in the disposition of tanshinol, a cardiovascular carboxylic catechol from Salvia miltiorrhiza roots (Danshen)
Aim: Tanshinol is an important catechol in the antianginal herb Salvia miltiorrhiza roots (Danshen). This study aimed to characterize tanshinol methylation. Methods: Metabolites of tanshinol were analyzed by liquid chromatography/mass spectrometry. Metabolism was assessed in vitro with rat and human enzymes. The major metabolites were synthesized for studying their interactions with drug metabolizing enzymes and transporters and their vasodilatory properties. Dose-related tanshinol methylation and its influences on tanshinol pharmacokinetics were also studied in rats. Results: Methylation, preferentially in the 3-hydroxyl group, was the major metabolic pathway of tanshinol. In rats, tanshinol also underwent considerable 3-O-sulfation, which appeared to be poor in human liver. These metabolites were mainly eliminated via renal excretion, which involved tubular secretion mainly by organic anion transporter (OAT) 1. The methylated metabolites had no vasodilatory activity. Entacapone-impaired methylation did not considerably increase systemic exposure to tanshinol in rats. The saturation of tanshinol methylation in rat liver could be predicted from the Michaelis constant of tanshinol for catechol-O-methyltransferase (COMT). Tanshinol had low affinity for human COMT and OATs; its methylated metabolites also had low affinity for the transporters. Tanshinol and its major human metabolite (3-O-methyltanshinol) exhibited negligible inhibitory activities against human cytochrome P450 enzymes, organic anion transporting polypeptides 1B1/1B3, multidrug resistance protein 1, multidrug resistance-associated protein 2, and breast cancer resistance protein. Conclusion: Tanshinol is mainly metabolized via methylation. Tanshinol and its major human metabolite have low potential for pharmacokinetic interactions with synthetic antianginal agents. This study will help define the risk of hyperhomocysteinemia related to tanshinol methylation.
- 20 April 2015
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 36 (5) , 627-643
Open AccessMethylation and its role in the disposition of tanshinol, a cardiovascular carboxylic catechol from Salvia miltiorrhiza roots (Danshen)
Aim: Tanshinol is an important catechol in the antianginal herb Salvia miltiorrhiza roots (Danshen). This study aimed to characterize tanshinol methylation. Methods: Metabolites of tanshinol were analyzed by liquid chromatography/mass spectrometry. Metabolism was assessed in vitro with rat and human enzymes. The major metabolites were synthesized for studying their interactions with drug metabolizing enzymes and transporters and their vasodilatory properties. Dose-related tanshinol methylation and its influences on tanshinol pharmacokinetics were also studied in rats. Results: Methylation, preferentially in the 3-hydroxyl group, was the major metabolic pathway of tanshinol. In rats, tanshinol also underwent considerable 3-O-sulfation, which appeared to be poor in human liver. These metabolites were mainly eliminated via renal excretion, which involved tubular secretion mainly by organic anion transporter (OAT) 1. The methylated metabolites had no vasodilatory activity. Entacapone-impaired methylation did not considerably increase systemic exposure to tanshinol in rats. The saturation of tanshinol methylation in rat liver could be predicted from the Michaelis constant of tanshinol for catechol-O-methyltransferase (COMT). Tanshinol had low affinity for human COMT and OATs; its methylated metabolites also had low affinity for the transporters. Tanshinol and its major human metabolite (3-O-methyltanshinol) exhibited negligible inhibitory activities against human cytochrome P450 enzymes, organic anion transporting polypeptides 1B1/1B3, multidrug resistance protein 1, multidrug resistance-associated protein 2, and breast cancer resistance protein. Conclusion: Tanshinol is mainly metabolized via methylation. Tanshinol and its major human metabolite have low potential for pharmacokinetic interactions with synthetic antianginal agents. This study will help define the risk of hyperhomocysteinemia related to tanshinol methylation.